Omidenepag isopropyl for the treatment of glaucoma and ocular hypertension.

• L. Ferrero Desideri ^[2] ; C. A. Cutolo ^[2] ; F. Barra ^[1] ; S. Ferrero ^[1] ; C.E. Traverso ^[2]
  1. [1] University of Genoa

     University of Genoa

     Genoa, Italia

     
  2. [2] (1) University Eye Clinic of Genoa, IRCSS Ospedale Policlinico San Martino, Genoa, Italy (2) Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 55, Nº. 6, 2019 (Ejemplar dedicado a: Junio), págs. 377-384
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Glaucoma is a main cause of irreversible vision impairment and its prevalence is expected to rise significantly in the near future. Among the current medications, prostaglandin analogues (PGAs) are widely used and considered as a first-line strategy in the management of glaucoma and ocular hypertension (OHT). However, given the non-negligible incidence of adverse ocular effects (conjunctival hyperemia, increase of iris pigmentation and eyelash changes) due to the use of this class of drugs, novel PGAs are being investigated. Omidenepag isopropyl is a selective prostaglandin EP2 receptor agonist which was approved on September 21, 2018, in Japan for the treatment of glaucoma and OHT. In this review, we will discuss its pharmacokinetics, pharmacodynam-ics and clinical efficacy, focusing also on its safety and tolerability profile.